What does DCGT stand for?

Division of Cellular and Gene Therapies (US FDA)

This definition appears very rarely and is found in the following Acronym Finder categories:

Military and Government
Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Double Cowgirls (macro-sized muskie spinnerbait) Dr. Challoner's Grammar School (est. 1624; UK) Distributed Common Ground System - Army Distributed Common Ground System-Air Force (US Air Force) Distributed Common Ground System-Intelligence Community (US DoD) Distributed Common Ground System-Marine Corps (US Marine Corps) Distributed Common Ground Station - Navy Distributed Common Ground System - Navy Detonation Cycle Gas Turbine Dielectric-Constant Gas Thermometer		Durham County Golf Union (UK) Development Company Greenport Venlo (Netherlands) D-Channel Handler Daily Chronic Headache Dansk Civile Hundeførerforening (Danish: Danish Civilian Dog Handler Association) Data Channel Data Clearing House Dedicated Channel Dedicated Transport Channel Defend Council Housing (UK)

Samples in periodicals archive:

Part of the need for a rule is that these are products of nature and in nature there are no rewards or punishments, only consequences," Philip Noguchi, the FDA's director of the Division of Cellular and Gene Therapies, told the committee.

FDA COMMITTEE WRESTLES WITH GENE THERAPY PRIVACY ISSUES

Philip Noguchi, director of the Food and Drug Administration's division of Cellular and Gene Therapies, addressed issues of safety in gene therapy trials at the June 16 roundtable at the La Jolla Marriott.

Jury Still Out on the Promises of Gene Therapy

; Philip Noguchi, director of the FDA's division of cellular and gene therapies at the Center for Biologics Evaluation and Research (CBER); Joyce Frey Vasconcells, deputy director of CBER's division of cellular and gene therapies; Amy Patterson, director of the Office of Biotechnology Activities at the National Institutes of Health; and Samuel Wadsworth, senior director of gene therapy at Genzyme.

BIO 2000 Examines Advances in Genomics, Gene Therapy

In preparation for the IND filing later this year, experts from the CBER Division of Cellular and Gene Therapies provided comments, guidance and clarification about the Agency's pre-clinical requirements for CY301 anti-herpes topical treatment.

CytoGenix Conducts Pre-IND FDA Conference for CY301 Herpes Cream

The speakers of this session will be: Darin Weber, Chief, Cellular Therapies Branch, Division of Cellular and Gene Therapies, FDA Gary du Moulin, Vice President, Quality Systems, Genzyme Biosurgery Rena Juliar, Director, Cell Processing Technology, IDM, Inc.

IDM Organizes a Workshop at BIO 2003 Conference in June